Patents by Inventor Jacob D. Johnson

Jacob D. Johnson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of manzamine compounds in anti-cancer therapeutic regimens
    Patent number: 8691801
    Abstract: Manzamine compounds have been discovered to decrease cell dissociation and cell migration associated with the metastatic potential of cancer cells and a restoration of cancer cell susceptibility to agents, such as TRAIL, which can induce apoptosis. Specifically, Manzamine A has a formerly unrecognized utility in both blocking tumor cell invasion and tumor metastasis as well in restoring cancer cell susceptibility to standard chemotherapeutic agents which induce apoptosis and, therefore, has utility in treating cancer.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: April 8, 2014
    Assignee: Florida Atlantic University Board of Trustees
    Inventors: Esther A. Guzman, Jacob D. Johnson, Amy E. Wright
  • Use of Manzamine Compounds in Anti-Cancer Therapeutic Regimens
    Publication number: 20120289533
    Abstract: Manzamine compounds have been discovered to decrease cell dissociation and cell migration associated with the metastatic potential of cancer cells and a restoration of cancer cell susceptibility to agents, such as TRAIL, which can induce apoptosis. Specifically, Manzamine A has a formerly unrecognized utility in both blocking tumor cell invasion and tumor metastasis as well in restoring cancer cell susceptibility to standard chemotherapeutic agents which induce apoptosis and, therefore, has utility in treating cancer.
    Type: Application
    Filed: July 17, 2012
    Publication date: November 15, 2012
    Inventors: Esther A. Guzman, Jacob D. Johnson, Amy E. Wright
  • Use of manzamine compounds in anti-cancer therapeutic regimens
    Patent number: 8232266
    Abstract: Manzamine compounds have been discovered to decrease cell dissociation and cell migration associated with the metastatic potential of cancer cells and a restoration of cancer cell susceptibility to agents, such as TRAIL, which can induce apoptosis. Specifically, Manzamine A has a formerly unrecognized utility in both blocking tumor cell invasion and tumor metastasis as well in restoring cancer cell susceptibility to standard chemotherapeutic agents which induce apoptosis and, therefore, has utility in treating cancer.
    Type: Grant
    Filed: February 20, 2007
    Date of Patent: July 31, 2012
    Assignee: Florida Atlantic University Board of Trustees
    Inventors: Esther A. Guzman, Jacob D. Johnson, Amy E. Wright